Arbutus Biopharma:Press Releases
Press Releases
SummaryToggleArbutusBiopharmaandBarinthusBioPresentPreliminaryDatafromPhase2aClinicalTrialCombiningImdusiranwithVTP-300at ...。其他文章還包含有:「AboutArbutus」、「ABUS-ArbutusBiopharmaCorporation」、「ArbutusBiopharma」、「ArbutusBiopharmaCorporation(ABUS)StockPrice」、「ArbutusBiopharmaCorporation(ABUS)公司概況及事件」、「ArbutusBiopharmaCorporation(ABUS)走勢圖」、「Home」、「InvestorRelati...
查看更多 離開網站About Arbutus
https://www.arbutusbio.com
We are a clinical-stage biopharmaceutical company with deep virology expertise and an unwavering focus on curing conditions with unmet medical need. Today, we' ...
ABUS-Arbutus Biopharma Corporation
https://www.moneydj.com
Arbutus Biopharma Corporation(ABUS.US)總部設在加拿大Burnaby,是一家生物製藥公司,在加拿大和美國開發和銷售治療慢性乙型肝炎(HBV)感染的療法。該公司還正在開發基於 ...
Arbutus Biopharma
https://en.wikipedia.org
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA ...
Arbutus Biopharma Corporation (ABUS) Stock Price
https://finance.yahoo.com
Find the latest Arbutus Biopharma Corporation (ABUS) stock quote, history, news and other vital information to help you with your stock trading and ...
Arbutus Biopharma Corporation (ABUS) 公司概況及事件
https://hk.finance.yahoo.com
查看Arbutus Biopharma Corporation (ABUS) 的公司概況,包括業務摘要、行業/板塊資訊、員工人數、企業管治、高級行政人員及其薪酬。
Arbutus Biopharma Corporation(ABUS) 走勢圖
https://tw.stock.yahoo.com
Arbutus Biopharma Corporation · 成交1.84 · 開盤1.82 · 最高1.86 · 最低1.81 · 一年內最高3.1500 · 買進1.8 · EPS (TTM)-0.4600 · PE Ratio(TTM). - ...
Home
https://www.arbutusbio.com
Arbutus is a virology-focused biotech on a mission to bring our clinical and pre-clinical assets to the patients that need them most.
Investor Relations
https://investor.arbutusbio.co
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and ...
Pipeline
https://www.arbutusbio.com
Our dynamic portfolio of virology assets includes a pipeline focused on curing HBV. Today, we have several active clinical studies, including approaches ...